[英语，临床]Suppressive effects of entecavir on hepatitis B virus and hepat

StephenW

<http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2011.06776.x/abstract;jsessionid=E5184F9703B77867BAC8F1BEDD741416.d03t03?systemMessage=Wiley+Online+Library+will+be+disrupted+21+May+from+10-12+BST+for+monthly+maintenance>

Suppressive effects of entecavir on hepatitis B virus and hepatocellular
carcinoma

Young-Joo Jin M.D.†, Ju Hyun Shim M.D.†, Han Chu Lee M.D., Dong-Jun Yoo
M.D., Kang Mo Kim M.D., Young-Suk Lim M.D., Dong Jin Suh M.D.

DOI: 10.1111/j.1440-1746.2011.06776.x
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell
Publishing Asia Pty Ltd Issue

Journal of Gastroenterology and Hepatology
Accepted Article (Accepted, unedited articles published online for future
issues)

Abstract

Background/Aim: We investigated the efficacy and effectiveness of entecavir
in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients.

Methods: We enrolled 231 nucleoside-naïve chronic hepatitis B (CHB)
patients primarily treated with entecavir 0.5 mg/day for at least 6 months
in our institution. Of these, 71 patients had HCC at the start of entecavir
treatment (HCC group) and 160 did not (non-HCC group). We compared
antiviral responses to entecavir in the two groups, and evaluated the
effects of entecavir on the clinical outcomes of curatively-treated HCC
patients.

Results: The HCC and non-HCC groups had similar cumulative rates of HBV-DNA
negativity, ALT normalization, and hepatitis e antigen loss in year 2 (100%
vs. 95.4%, 94.7% vs. 97.3%, and 40.8% vs. 41.8%, respectively; P > 0.05).
Entecavir treatment for 12 months decreased mean Model for End-Stage Liver
Disease scores in patients with cirrhosis and HCC (7.2 vs. 5.6, P < 0.001).
Of the 71 HCC patients, 16 underwent curative therapies concurrently with
entecavir; hepatectomy in six and radiofrequency ablation in ten, and the
55 remaining patients received transarterial chemoembolization or
conservative treatment. In a subgroup of 16 HCC patients receiving curative
treatments, patients who became serum HBV DNA negative by week 24 had
better overall survival (P= 0.039), but not recurrence-free survival (P=
0.961), than those who did not.

Conclusions: First-line entecavir monotherapy is comparably effective in
CHB patients with and without HCC, and improves hepatic function in
HBV-related HCC patients. An early virological response to entecavir is
prognostic of improved survival following curative therapy against
HBV-related HCC.



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

恩替卡韦抑制性影响乙肝病毒与肝细胞癌

杨柱进医师†，朱铉沉医师†，韩楚肋鹅医师董军柳
医学博士，康沫金医师杨淑林医师董奇嗯Suh博士

分类号：10.1111/j.1440-1746.2011.06776.x
© 2011年胃肠病学和肝病基金会和Blackwell
亚洲私人有限公司出版发行

胃肠病学和肝病
接受第（接受，为未来网上发表文章未经编辑
问题）

摘要

背景/目的：我们研究的有效性和效率的恩替卡韦
乙型肝炎病毒（HBV）相关肝细胞癌（HCC）患者。

方法：我们收集231核苷初治慢性乙型肝炎（CHB）
恩替卡韦治疗的患者主要是0.5毫克/天，至少6个月
在我们的机构。其中，71名曾在恩替卡韦开始肝癌
治疗（肝癌组）和160没有（非肝癌组）。我们比较
恩替卡韦抗病毒反应，在两个组，并评估了
对恩替卡韦的治疗性治疗的肝癌的临床疗效
病人。

结果：肝癌与非肝癌组有HBV - DNA的相似率累计
消极，谷丙转氨酶正常化，肝炎e抗原在第2年亏损（100％
主场迎战95.4％，94.7％，97.3％，41.8％和40.8对比，分别％; P> 0.05）。
恩替卡韦治疗12个月降低平均为终末期肝病模型
肝硬化并肝癌（7.2对比5.6，磷“0.001）患者的疾病得分。
在71个肝癌病人，16例疗效与治疗同时
恩替卡韦，在六肝切除术和射频消融十，而
其余55位病人接受化学栓塞或
保守治疗。在16名病患接受治疗肝癌
治疗，患者谁成为24周了血清HBV DNA阴性
更好的整体存活率（P = 0.039），但不无复发存活率（P =
0.961），比那些谁没有。

结论：第一线替卡韦单一疗法相对比较有效
慢性乙型肝炎患者和无肝癌，肝功能，提高
HBV相关肝癌患者。早期病毒学应答对恩替卡韦是
改良根治性治疗后存活预后反对
HBV相关肝癌。